Terminalia catappa Linn. is known for its nutritional fruit and possesses medicinal benefits as well. This is a comprehensive review of the phytoconstituents and pharmacological benefits. T. catappa has been recognized for its medicinally essential phytoconstituents, such as phenol, flavonoid, and carotenoid. Numerous pharmacological investigations have confirmed this plant's ability to exhibit antimicrobial, anti-inflammatory, antidiabetic, antioxidant, hepatoprotective, and anticancer activities, all of which support its traditional uses.

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome corona virus-2 (SARS-CoV-2), is the most important health issue, internationally. With no specific and effective antiviral therapy for COVID-19, new or repurposed antiviral are urgently needed. Phytochemicals pose a ray of hope for human health during this pandemic, and a great deal of research is concentrated on it. Phytochemicals have been used as antiviral agents against several viruses since they could inhibit several viruses via different mechanisms of direct inhibition either at the viral entry point or the replication stages and via immunomodulation potentials. Recent evidence also suggests that some plants and its components have shown promising antiviral properties against SARS-CoV-2. This review summarizes certain phytochemical agents along with their mode of actions and potential antiviral activities against important viral pathogens. A special focus has been given on medicinal plants and their extracts as well as herbs which have shown promising results to combat SARS-CoV-2 infection and can be useful in treating patients with COVID-19 as alternatives for treatment under phytotherapy approaches during this devastating pandemic situation.

Post COVID-19, mucormycosis occurred after the SARS-CoV-2 has rampaged the human population and is a scorching problem among the pandemic globally, particularly among Asian countries. Invasive mucormycosis has been extensively reported from mild to severe COVID -19 survivors. The robust predisposing factor seems to be uncontrolled diabetes mellitus, comorbidity and immunosuppression acquired through steroid therapy. The prime susceptive reason for the increase of mucormycosis cases is elevated iron levels in the serum of the COVID survivors. A panoramic understanding of the infection has been elucidated based on clinical manifestation, genetic and non- genetic mechanisms of steroid drug administration, biochemical pathways and immune modulated receptor associations. This review lime-lights and addresses the “What”, “Why”, “How” and “When” about the COVID-19 associated mucormycosis (CAM) in a comprehensive manner with a pure intention to bring about awareness to the common public as the cases are inevitably and exponentially increasing in India and global countries as well. The article also unearthed the pathogenesis of mucormycosis and its association with the COVID-19 sequela, the plausible routes of entry, diagnosis and counter remedies to keep the infection at bay. Cohorts of case reports were analysed to spotlight the link between the pandemic COVID-19 and the nightmare-mucormycosis.

Objective: The present investigation includes the preliminary screening of phytochemicals and evaluation of an in vitro antidiabetic activity of Psidium guajava leaves extracts. Materials and Methods: Plant material was subjected to the extract preparation by soxhlet apparatus by using various solvents such as aqueous, ethanol, chloroform, petroleum ether and hexane. The various kinds of phytochemicals were detected and then in vitro antidiabetic activity of P. guajava leaves were detected by using alpha amylase and alpha glucosidase enzyme in an in vitro model. Results: The study reveals the presence of phytochemicals such as carbohydrate, tannin, flavonoids, phenols etc., Among the various extracts the aqueous and ethanolic extracts which contains the large number of phytoconstituents. The P. guajava leaves has been successfully inhibited both the enzymes in an in vitro model. The aqueous extracts of P. guajava leaves inhibited the alpha amylase and alpha glucosidase enzymes as 72.1% and 74.8%respectively. The ethanolic extract of P. guajava leaves inhibited the alpha amylase and alpha glucosidase enzymes as 97.5% and 91.8% respectively. Conclusion: From the results obtained in the current studies, the P. guajava leaves have a prominent antidiabetic property in an in vitro model and further studies can be carried out in an in vivo model and the isolation of activie compound from P. guajava leaves extract is needed.

Newly emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) pandemic has now spread across the globe in past few months while affecting 26 million people and leading to more than 0.85 million deaths as on 2nd September, 2020. Severity of SARS-CoV-2 infection increases in COVID-19 patients due to pre-existing health co-morbidities. This mini-review has focused on the three significant co-morbidities viz., heart disease, hypertension, and diabetes, which are posing high health concerns and increased mortality during this ongoing pandemic. The observed co-morbidities have been found to be associated with the increasing risk factors for SARS-CoV-2 infection and COVID-19 critical illness as well as to be associated positively with the worsening of the health condition of COVID-19 suffering individuals resulting in the high risk for mortality. SARS-CoV-2 enters host cell via angiotensin-converting enzyme 2 receptors. Regulation of crucial cardiovascular functions and metabolisms like blood pressure and sugar levels are being carried out by ACE2. This might be one of the reasons that contribute to the higher mortality in COVID-19 patients having co-morbidities. Clinical investigations have identified higher levels of creatinine, cardiac troponin I, alanine aminotransferase, NT-proBNP, creatine kinase, D-dimer, aspartate aminotransferase and lactate dehydrogenase in patients who have succumbed to death from COVID-19 as compared to recovered individuals. More investigations are required to identify the modes behind increased mortality in COVID-19 patients having co-morbidities of heart disease, hypertension, and diabetes. This will enable us to design and develop suitable therapeutic strategies for reducing the mortality. More attention and critical care need to be paid to such high risk patients suffering from co-morbidities during COVID-19 pandemic.